FDA E&M Division Director Is Lipid Drug Team Leader Orloff
Executive Summary
FDA's Endocrine & Metabolic Drug Products Division Director David Orloff, MD, brings six years of experience within the E&M division in reviewing lipid-regulating agents.
You may also be interested in...
ODE II Director Jenkins Assumes Acting Title As Head Of E&M
FDA Office of Drug Evaluation II Director John Jenkins, MD, is serving as acting director of FDA's Endocrine & Metabolic Drug Products Division following the departure Solomon Sobel, MD, to the Office of Review Management.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials